N/A N=500 Reducing Post-Hospital Mortality in HIV-infected Adults in Tanzania
HIV Infections
Primary: Number of Participant Deaths in the First 12 Months Post-hospitalization — 43; 42 Participants — p=0.91
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=80 Caring Cards to and From Veterans: A Peer Approach to Suicide Prevention
Feasibility · Acceptability · Thwarted Belongingness
Primary: Feasibility — 242; 234; 212; 233 Participants
N/A N=70 Brain Mechanisms of Reducing Polysubstance Use Following a Novel Body-mind Intervention
Multiple Drug Use
Primary: Brain Changes in Functional Activity — 0.7; 0.6; 1.3; 0.9 beta weights — p=0.03
N/A N=600 Diabetes Outcomes and Unmet Resources
Diabetes
Primary: Change in HbA1c as Measured by an HbA1c Machine — 0.07; -0.10 percentage of average glucose 3 months
Phase 2 N=133 Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3)
Cervical Intraepithelial Neoplasia · Cervical Dysplasia
Primary: Incidence of Objective Response — 32; 36; 30; 0 Participants — p=0.043
Phase 2 N=108 Study of Sequential GSK3228836 and Peginterferon Treatment in Participants With Chronic Hepatitis B (CHB)
Hepatitis B
Primary: Treatment Arm 1 - Percentage of Participants Achieving Sustained Virologic Response (SVR) for 24 Weeks After End of Treatment — 9 Percentage of Participants
N/A N=163 Hypofractionated SBRT For Prostate Cancer
Prostate Cancer
Primary: Rate of Acute Grade 3 or Higher GI and GU Toxicities — 2 Participants
Early Phase 1 N=44 Inpatient Single Dose Interventions for Alcohol Use Disorder
Alcohol Use Disorder, Severe
Primary: Rate (%) of 30-day Hospital Re-admission — 3; 2; 7 Participants
N/A N=32 Activating and Connecting Teens (ACT) Study
Depression
Primary: Depression — 9.63 score on a scale
Phase 2 N=20 Combination Drug-Therapy for Patients With Untreated Obstructive Sleep Apnea
OSA · Obstructive Sleep Apnea
Primary: Apnea Hypopnea Index (AHI) — 17.1; 32.7; 26; 23.6 events/hour of sleep
Phase 2 N=6 Safety and Efficacy of CIS43LS Anti-malaria mAb in Mali
Plasmodium Falciparum Infection · Malaria
Primary: Participants With Local Adverse Events (AEs) — 1; 0; 0; 2 Participants
N/A N=31 A Study to Evaluate 4DCT Controls
Wrist Ligament and Bone Disorders
Primary: Scapholunate (SL) Gapping — 1.65; 1.64; 1.86; 1.92 millimeters
Phase 2 N=195 P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC
Carcinoma, Squamous Cell · Head and Neck Neoplasms · Oropharyngeal Neoplasms
Primary: Progression Free Survival (PFS) — 3; 6; 0; 8 Participants
N/A N=849 Peer Support for Weight Loss Maintenance
Obesity
Primary: Weight Change (kg) — 1.2; 2.5 kilograms
N/A N=142 Evaluation of Microcirculatory Function and Mitochondrial Respiration After Cardiovascular Surgery
Shock · Cardiovascular Diseases · Critical Illness
Primary: Perfused Vessel Denisty (PVD) — 22.8; 23.8; 20.2; 22.5 mm/mm^2